Statement Of Cash Flows [Abstract]

Mithra Pharmaceuticals S.A. - Filing #3183197

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
As at
2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
74,387,000 EUR
80,025,000 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
- EUR
23,000 EUR
Purchase of property, plant and equipment, classified as investing activities
11,483,000 EUR
10,645,000 EUR
Purchase of intangible assets, classified as investing activities
9,699,000 EUR
5,585,000 EUR
Cash flows from (used in) investing activities
54,682,000 EUR
16,207,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
9,213,000 EUR
65,731,000 EUR
Payments of lease liabilities, classified as financing activities
7,193,000 EUR
3,475,000 EUR
Proceeds from government grants, classified as financing activities
41,000 EUR
5,835,000 EUR
Interest paid, classified as financing activities
11,765,000 EUR
3,503,000 EUR
Cash flows from (used in) financing activities
23,245,000 EUR
185,187,000 EUR
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
21,000 EUR
- EUR
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
105,824,000 EUR
88,954,000 EUR
Cash and cash equivalents
32,872,000 EUR
138,675,000 EUR
49,720,000 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.